SCHEDULE: ExodusPoint Discloses 6.3% Stake in Keros Therapeutics
Beneficial Ownership Disclosure
ExodusPoint Capital Management, along with its affiliates, has reported a 6.3% beneficial ownership stake in Keros Therapeutics, Inc., totaling 1,907,899 shares.
Summary
- ExodusPoint Capital Management, LP, ExodusPoint Capital Partners GP, LLC, and Michael Gelband (collectively, the "Reporting Persons") have filed a Schedule 13G.
- The filing discloses beneficial ownership of 1,907,899 shares of Common Stock, $0.0001 par value per share, in Keros Therapeutics, Inc.
- This represents approximately 6.3% of Keros Therapeutics, Inc.'s outstanding Common Stock.
- The shares are held directly by ExodusPoint Partners Master Fund, LP, an investment fund managed by ExodusPoint Capital Management.
- ExodusPoint Capital Management, ExodusPoint Capital Partners, and Michael Gelband collectively hold shared voting and shared dispositive power over all 1,907,899 shares.
- The Reporting Persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The filing reports a significant passive institutional investment, which is generally a neutral to slightly positive signal, but provides no operational or financial performance data for Keros Therapeutics, Inc.
Positives
- A significant institutional investor, ExodusPoint Capital Management, has disclosed a 6.3% beneficial ownership stake in Keros Therapeutics, Inc., which can be interpreted as a vote of confidence in the company.
Risks
- The Reporting Persons certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating potential activist investor risks.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding Keros Therapeutics, Inc.'s future performance or operations.
Industry Context
This filing represents a standard disclosure of a significant passive institutional investment in a publicly traded biotechnology company, Keros Therapeutics, Inc. It reflects an investment decision by a hedge fund, ExodusPoint Capital Management, to hold a substantial stake in the company's common stock.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Joint Filing Agreement | ExodusPoint Capital Management, LP, ExodusPoint Capital Partners GP, LLC, and Michael Gelband entered into a Joint Filing Agreement to file this Schedule 13G jointly. | 11/18/2025 | Ensures compliance with SEC Rule 13d-1(k) for group filings, clarifying shared responsibility for timely and accurate amendments concerning their respective information. |
Stakeholder Impact
- Shareholders of Keros Therapeutics, Inc. may view the disclosure of a 6.3% stake by an institutional investor like ExodusPoint Capital Management as a positive signal, potentially indicating confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 11/10/2025 | Date of event which required the filing of this statement |
| 11/17/2025 | Date as of which the amount beneficially owned was calculated |
| 11/18/2025 | Date of the Joint Filing Agreement and signing of the Schedule 13G |
Keywords
Keros Therapeutics, ExodusPoint Capital Management, Schedule 13G, beneficial ownership, institutional investment, common stock, equity stake, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.